IRCT20191126045505N1
Completed
Phase 3
The effects of empagliflozin on neuropathy and retinopathy outcomes, renal function, and quality of life in patients with type 2 diabetes in Bojnurd
Bojnourd University of Medical Sciences0 sites100 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Bojnourd University of Medical Sciences
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Type 2 diabetic patients who have been diagnosed for at least 6 months and treated at least with two anti\-diabetic drugs.
- •BMI\= Kg/m245
Exclusion Criteria
- •Liver Failure
- •Type1 diabetes
- •History of ketosis
- •History of frequent falls and recurrent infections
- •Significant renal disease requiring dialysis
- •Inappropriate drug use
- •Serious medical conditions such as severe cardiovascular disease such as heart attack or stroke in the last three months
- •Blood pressure above 180/110 mmHg
- •Major surgery performed in the last 28 days
- •Cancer treatment in the past 5 years
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
Recruiting
Phase 4
A study examining the effects of empagliflozin (Jardiance®), a tablet for treatment of diabetes on autonomic nervous system and heart function in patients with type 2 diabetes.Type 2 DiabetesMetabolic and Endocrine - DiabetesCardiovascular - Normal development and function of the cardiovascular systemACTRN12619000887178Baker Heart and Diabetes Institute60
Completed
N/A
The effect of empagliflozin on diuresis and neurohumoral factors in the patients with decompensated heart failure and diabetes mellitus: pilot studydecompensated heaat failure type 2 diabetes mellitusJPRN-UMIN000027431Department of Cardiology, National Hospital Organization Yokohama Medical Center15
Not Yet Recruiting
Phase 2
Assessment of extra-renal effects of SGLT2-inhibitors in anuric haemodialysis patients using microneurographyACTRN12623001237673Dobney Hypertension Centre20
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90